Gyre Therapeutics, Inc. GYRE Accounts Receivable
Accounts Receivable at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsReceivableNetCurrent.
The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Gyre Therapeutics, Inc.'s accounts receivable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Gyre Therapeutics, Inc.'s accounts receivable?
- Gyre Therapeutics, Inc. (GYRE) reported accounts receivable of $22.76M in Q1 2026.
- How has Gyre Therapeutics, Inc.'s accounts receivable changed year-over-year?
- Gyre Therapeutics, Inc.'s accounts receivable increased by 13.0% year-over-year, from $20.15M to $22.76M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s accounts receivable?
- Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s accounts receivable has grown at a 103.7% compound annual growth rate (CAGR), from $5.91M to $101.73M.
- What does accounts receivable mean?
- Amounts owed by customers for goods delivered or services performed, net of allowances for doubtful accounts. A key working capital component.